Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
arcanepeptides.com
Samples
Passed
Failed
Trust score updated: May 28, 2026 · 100% pass rate
Composite score based on 25 COAs attributed to this vendor.
Mean HPLC purity across published COAs
Per-peptide coverage of identity / endotoxin / microbial / heavy-metals / net-content panels
Lab corroboration tier — confirmed via public verify portal (90), presumptive trusted lab (85), lab resolved but unverified (75), or no lab attribution (50)
Inverse of CoaFlag count (lot collisions, hash collisions, etc.)
Composite of 25 COAs attributed to this vendor. Last recomputed 2026-05-28.
| Date | Peptide | Test | Result | Purity | Lab | Notes |
|---|---|---|---|---|---|---|
| May 24, 2026 | TB-500 (Tβ4) | HPLC purity | PASS | 99.19% | Chromate | Lot TB002 · Report 35380 |
| May 24, 2026 | Semax | HPLC purity | PASS | 98.749% | Chromate | Lot SX002 · Report 35369 |
| Apr 22, 2026 | GLOW 70mg | HPLC purity | PASS | 99.776% | Chromate | Lot GL0002 · Report 34238 |
We are continuously testing more products. Scores update with each new result.
Read our scoring methodology →Trust scores are computed from indexed Certificates of Analysis — vendor-published, and lab-confirmed where a lab copy verifies them — using a fixed, versioned methodology (v13). They are not based on independent blind-purchase testing, and no vendor can pay for placement or a higher score. How we score · How we make money
No phone number (-0.03), No physical address (-0.03), No business entity (-0.03)
Sources: RDAP/WHOIS for domain data, Twilio Lookup for phone classification, Google Places for address verification. Crawl runs weekly. Signals are independent of vendor-supplied data.
| Apr 22, 2026 | Melanotan I | HPLC purity | PASS | 99.609% | Chromate | Lot MT102 · Report 34168 |
| Apr 22, 2026 | Selank | HPLC purity | PASS | 99.656% | Chromate | Lot SK002 · Report 34242 |
| Apr 22, 2026 | Melanotan II | HPLC purity | PASS | 99.14% | Chromate | Lot MT202 · Report 34171 |
| Apr 22, 2026 | — | Identity & safety panels | PASS | -- | Chromate | Lot BA002 · Report 34249 |
| Apr 13, 2026 | PT-141 | HPLC purity | PASS | 99.01% | Vanguard Laboratory | Lot PT402 · Report V260410-23 009 |
| Mar 29, 2026 | hCG | Identity & safety panels | PASS | -- | Chromate | Lot HCG002 · Report 33588 |
| Mar 23, 2026 | Dapoxetine | Identity & safety panels | PASS | -- | Chromate | Lot DAP001 · Report 33375 |
| Mar 19, 2026 | GHK-Cu | HPLC purity | PASS | 99.637% | Chromate | Lot GHK102 · Report 33563 |
| Mar 19, 2026 | GHK-Cu | HPLC purity | PASS | 99.966% | Chromate | Lot GHK002 · Report 33560 |
| Mar 18, 2026 | BPC-157 | HPLC purity | PASS | 98.353% | Chromate | Lot BPC002 · Report 33552 |
| Mar 4, 2026 | NAD+ | HPLC purity | PASS | 98.59% | Vanguard Laboratory | Lot NAD002 · Report V260226-6 001 |
| Mar 4, 2026 | HCG | Identity & safety panels | PASS | -- | Vanguard Laboratory | Lot HCG002 · Report V260226-6 006 |
| Feb 16, 2026 | CJC-1295 (mod GRF 1-29) + Ipamorelin | Identity & safety panels | PASS | -- | Janoshik Analytical | Report 109341 |
| Feb 16, 2026 | CJC-1295 DAC | HPLC purity | PASS | 99.842% | Janoshik Analytical | Report 109340 |
| Feb 13, 2026 | Teriparatide | HPLC purity | PASS | 99.566% | Janoshik Analytical | Report 109339 |
| Jan 23, 2026 | AOD-9604 | HPLC purity | PASS | 99.77% | Janoshik Analytical | Report 102678 |
| Jan 21, 2026 | Tesamorelin | HPLC purity | PASS | 99.151% | Janoshik Analytical | Report 101355 |
| Dec 23, 2025 | PP405 | Identity & safety panels | PASS | -- | Chromate | Lot ARCANE8BEW9R · Report 30637 |
| Jun 4, 2026 | IGF-1 LR3 | HPLC purity | PASS | 98.64% | Vanguard Laboratory | Lot IGF102 · Report V260406-1 008 |
| Jun 4, 2026 | Ipamorelin | HPLC purity | PASS | 99.8% | Vanguard Laboratory | Lot IPA002 · Report V260406-1 013 |
| Jun 4, 2026 | Retatrutide | HPLC purity | PASS | 99.8% | Vanguard Laboratory | Lot RT1002 · Report V260226-6 004 |
| Jun 4, 2026 | BPC-157/TB-500 | HPLC purity | PASS | 99.8% | Vanguard Laboratory | Lot BT002 · Report V260406-1 011 |